Solventum Financial Ratios
NYSE: SOLVHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Solventum ratio analysis
Solventum earned a net margin of 18.7% in FY 2025, up from 5.8% a year earlier. Gross margin was 53.5% compared with a median of 57.3% over the prior 3 years. Return on equity reached 30.8%, meaning Solventum generated 0.31 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.00 versus 2.71 the year before, and the current ratio was 1.23. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Solventum financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 8.90 | 24.32 | — | — |
| Price / sales | 1.65 | 1.41 | — | — |
| Price / book | 2.72 | 3.93 | — | — |
| Gross margin | 53.5% | 55.6% | 57.3% | 57.7% |
| Operating margin | 26.2% | 12.6% | 20.6% | 20.8% |
| Net margin | 18.7% | 5.8% | 16.4% | 16.5% |
| Free cash flow margin | -0.1% | 9.8% | 19.8% | 17.6% |
| Return on equity (ROE) | 30.8% | 16.2% | 11.5% | 11.4% |
| Return on assets (ROA) | 10.9% | 3.3% | 9.7% | — |
| Debt / equity | 1.00 | 2.71 | 0.00 | — |
| Current ratio | 1.23 | 1.20 | 1.46 | — |
| Revenue growth | 0.9% | 0.7% | 0.8% | — |
| EPS growth | 221.7% | -64.6% | 0.1% | — |